# Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Source: https://onco.cc/trials/nct00083382/  
OnCo record `nct00083382` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pamidronate, Thalidomide and Zoledronic acid in Multiple myeloma, run by University of Arkansas, completed.

## Summary

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide is a phase 2 interventional study registered as NCT00083382 by University of Arkansas, with 83 participants recorded, started 1998-12 and reaching its primary completion in 2014-05. Interventions recorded: Pamidronate, Thalidomide, Zometa. Conditions recorded: Multiple Myeloma.

Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00083382
- Phase: 2
- Setting: UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma
- Sponsor: University of Arkansas
- Enrolled: 83

## Sources

- ClinicalTrials.gov NCT00083382: https://clinicaltrials.gov/study/NCT00083382

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Pamidronate](https://onco.cc/drugs/pamidronate/), [Thalidomide](https://onco.cc/drugs/thalidomide/), [Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/)

---
JSON: https://onco.cc/api/v1/entities/nct00083382.json